c-Fms

<p>Edicotinib (JNJ-527) is a blood-brain permeable, selective CSF-1R inhibitor, with lesser inhibitory effects on KIT and FLT3.Cost-effective and quality-assured.</p>

<p>Emactuzumab(RG 7155) is a monoclonal antibody against colony-stimulating factor-1 receptor targeting tumor-associated macrophages (TAMs) Emactuzumab has</p>

<p>Lacnotuzumab (MCS110) is a humanized monoclonal antibody targeting CSF-1, which can be used in research on retinal diseases.</p>

<p>CSF1R-IN-1 is a CSF1R inhibitor with IC50 of 0.5 nM.</p>

<p>Axatilimab (SNDX-6352) is a human IgG4 antibody that targets CSF-1R and can be used to study immune system diseases and respiratory diseases.</p>

<p>Mavrilimumab (CAM 3001), a monoclonal antibody, blocks GM-CSF signaling, potentially reducing inflammation in rheumatoid arthritis.</p>

<p>CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).</p>

<p>PXB17 inhibits CSF1R activation (IC50= 1.7 nM) by blocking the PI3K/AKT/mTORC1 signaling pathway. It is effective orally, significantly suppresses the growth of colorectal cancer (CRC), enhances the efficacy of PD-1 monoclonal antibodies (PD-1mAb), and reduces the recurrence of CRC tumors.</p>

<p>M4205 is an inhibitor of c-Kit exhibiting high activity on c-Kit mutations in exons 11, 13, 17.</p>

<p>CSF1R-IN-17 (compound 9) is a potent, selective antagonist of CSF1R, exhibiting an inhibition concentration half-maximum (IC50) of 0.2 nM.</p>

<p>Pyrithyldione is a sedative-hypnotic agent known to potentially induce agranulocytosis.</p>

<p>AMG-820 is a human antibody targeting CSF-1R, inhibiting the binding of ligands CSF1 and IL34, and preventing subsequent ligand-induced receptor activation. For AMG-820's isotype control, refer to [Human IgG2 kappa, Isotype Control].</p>

<p>PLX647 dihydrochloride: potent FMS/KIT inhibitor (IC50: 28/16 nM), highly selective, limited FLT3/KDR activity, oral use.</p>

<p>cFMS Receptor Inhibitor IV is an inhibitor of c-Fms tyrosine kinase.</p>

<p>Otilimab, a humanized monoclonal antibody, blocks GM-CSF to reduce inflammation and may treat severe COVID-19 pneumonia.</p>

<p>Sotuletinib hydrochloride (BLZ945 HCl) is a selective, brain-penetrant CSF-1R (c-Fms) inhibitor (IC50=1 nM),for ALS and TNBC.</p>

<p>GENZ-882706(Raceme) is the racemate of GENZ-882706.</p>

<p>PD-360324 is a human monoclonal antibody (mAb) that targets CSF1/M-CSF. It can be utilized in research related to skin lupus, pulmonary sarcoidosis, and rheumatoid arthritis.</p>

<p>Antifibrotic agent 1 is an orally active medication designed to treat idiopathic pulmonary fibrosis (IPF). It effectively mitigates IPF-related processes, including TGF-β-induced epithelial-mesenchymal transition (EMT) and fibroblast-to-myofibroblast transition (FMT), as well as profibrotic M2 polarization. Antifibrotic agent 1 selectively inhibits CSF-1R, PDGFR-α, and Src family kinases (SFKs), while sparing VEGFR, FGFR, and Abl to minimize off-target toxicity. In a bleomycin (BLM)-induced pulmonary fibrosis mouse model, it demonstrates strong antifibrotic activity.</p>

<p>Plonmarlimab(TJ003234) is an anti-GM-CSF monoclonal antibody with potential antiviral activity for the study of immune disorders and novel coronavirus infection</p>

<p>Eflapegrastim: humanized IgG4 antibody and G-CSF that boosts neutrophils and shortens neutropenia.</p>

<p>Gimsilumab (MORAb-022) is an anti-c-Fms humanized monoclonal antibody for the study of inflammation and hypoxemia caused by COVID-19.</p>

<p>M-CSFR/CSF1R/CD115 Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag.</p>

<p>Anti-CSF1R Antibody (1R707) is a Rabbit antibody targeting CSF1R. Anti-CSF1R Antibody (1R707) can be used in ELISA.</p>

<p>Anti-CSF1R Antibody (2I506) is a Mouse antibody targeting CSF1R. Anti-CSF1R Antibody (2I506) can be used in ELISA.</p>

<p>Anti-CSF1R Antibody-FITC (4Y587) is a FITC-conjugated Mouse antibody targeting CSF1R. Anti-CSF1R Antibody-FITC (4Y587) can be used in FCM.</p>

<p>Anti-CSF1R Antibody (7V18) is a Rabbit antibody targeting CSF1R. Anti-CSF1R Antibody (7V18) can be used in ELISA.</p>

<p>Anti-CSF1R Antibody (8O797) is a Mouse antibody targeting CSF1R. Anti-CSF1R Antibody (8O797) can be used in ELISA.</p>

<p>Anti-CSF1R Antibody (5B661) is a Mouse antibody targeting CSF1R. Anti-CSF1R Antibody (5B661) can be used in ELISA,ELISA(Cap).</p>

<p>Anti-CSF1R Antibody (5C535) is a Rabbit antibody targeting CSF1R. Anti-CSF1R Antibody (5C535) can be used in ELISA.</p>

<p>CSF1R Protein, Human, Recombinant (His &amp; Avi), Biotinylated is expressed in HEK293 mammalian cells with His and Avi tag.</p>

<p>CSF1R Protein (Met1-Glu512), Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag.</p>

<p>CSF1R Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag.</p>

<p>M-CSFR/CSF1R/CD115 Protein, Human, Recombinant (His &amp; Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag.</p>

<p>CSF1R Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 55.1 kDa and the accession number is P07333-1.</p>

<p>CSF1R Protein, Human, Recombinant (His &amp; GST) is expressed in Baculovirus insect cells with His and GST tag.</p>

<p>CSF1R Protein, Human, Recombinant (mFc) is expressed in HEK293 mammalian cells with mFc tag.</p>

<p>CSF1R Protein (Ala299-Glu512), Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag.</p>

<p>CSF1R Protein, Human, Recombinant (hFc &amp; Avi), Biotinylated is expressed in HEK293 mammalian cells with hFc and Avi tag.</p>

<p>CSF1R Protein, Human, Recombinant (Domain I&amp;II&amp;III, His) is expressed in HEK293 mammalian cells with His tag.</p>

<p>PLX647 is a highly selective dual FMS/KIT kinase inhibitor (IC50: 28/16 nM).</p>

<p>M-CSFR/CSF1R/CD115 Protein, Human, Recombinant (His &amp; Avi) is expressed in HEK293 mammalian cells with C-His-Avi tag.</p>

<p>Anti-CSF1R Antibody (4Y587) is a Mouse antibody targeting CSF1R. Anti-CSF1R Antibody (4Y587) can be used in FCM.</p>

<p>Pazopanib HCl (Votrient) inhibits VEGFR1-3, PDGFR, FGFR, c-Kit, c-Fms with IC50 range 10-146 nM in cell-free assays.</p>

<p>Seralutinib (GB002) is an inhibitor of inhaled PDGFRα and PDGFRβ. It is used in the study for pulmonary arterial hypertension.</p>

<p>AZD7507 is a CSF-1R inhibitor with an IC50 of 32 nM. AZD7507 has antitumor activity.</p>

<p>PRN1371 is a specific and potent FGFR1-4 and CSF1R inhibitor (IC50s: 0.6/1.3/4.1/19.3/8.1 nM for FGFR1/2/3/4 and CSF1R).</p>

<p>Pexidartinib (PLX-3397) is a capsule formulation containing a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential</p>

<p>cFMS Receptor Inhibitor II is a CSF1R kinase inhibitor</p>

<p>PF 477736 (PF-736,PF-00477736) is a specifc, effective and ATP-competitive Chk1 inhibitor (Ki: 0.49 nM ) and also inhibits FGFR3, Aurora-A, VEGFR2, Flt3, Fms (</p>

<p>Ki-20227 is a specific c-Fms tyrosine kinase(CSF1R) inhibitor (IC50: 2 nM).</p>

<p>Vimseltinib (DCC-3014) is a c-FMS (CSF-IR) and c-Kit dual inhibitor (IC50s: &lt;0.01 μM and 0.1-1 μM).</p>

<p>Sotuletinib (BLZ945) is an orally active, effective and specific CSF-1R inhibitor, &gt;1000-fold selective against its closest receptor tyrosine kinase homologs.</p>

<p>AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits BRAF (WT), BRAF (V600E), and wild type CRAF (IC50s: 79/38/68 nM).</p>

<p>GW2580 (SC-203877) is a specific, oral-bioavailable CSF-1R inhibitor for c-FMS.</p>

<p>PLX5622 is a selective, orally active and blood-brain barrier permeable CSF1R inhibitor. PLX5622 induces elimination of microglia. Cost effective and quality assured.</p>

<p>Linifanib (AL-39324) (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR (IC50: 4 nM), CSF-1R (IC50: 3 nM), Flt-1/3 (IC50: 3/4 nM) and</p>

<p>Nampt-IN-1 (LSN3154567) (LSN3154567) is a potent and selective NAMPT inhibitor. Nampt-IN-1 inhibits purified NAMPT with an IC50 of 3.1 nM.</p>

<p>OSI-930 is an oral c-Kit/VEGFR-2 inhibitor targeting tumor growth and angiogenesis.</p>

<p>Dovitinib is an orally active, multi-targeted tyrosine kinase (RTK) inhibitor with anti-tumor effects.Cost-effective and quality-assured.</p>

<p>Anumigilimab (CSL-324) is a fully human therapeutic anti-G-CSFR antibody with potential anti-tumor activity for the study of inflammation.</p>

<p>Lenzilumab (KB 003) is a humanized GM-CSF neutralizing antibody for the study of COVID-19.</p>

<p>Namilumab (AMG203) is a humanised IgG1 monoclonal antibody that neutralises GM-CSF. rheumatoid arthritis and active axial spondyloarthritis.</p>

<p>Trabikibart (CSL311) is a human βc-specific antibody inhibiting IL-3, GM-CSF and IL-5, regulating eosinophil survival in chronic inflammatory disease research.</p>

<p>Cabiralizumab is an anti-CSF1R monoclonal antibody that enhances T cell infiltration, inhibits osteoclasts, and is used in RA and immune-oncology research.</p>

<p>Anti-Mouse GM-CSF Antibody is a rat-derived IgG2a isotype inhibitor that targets mouse granulocyte-macrophage colony-stimulating factor (GM-CSF).</p>

<p>CSF1R-IN-19 is a robust inhibitor of CSF1R that influences the exchange of inflammatory factors between TAMs and glioma cells. It holds potential for cancer research [1].</p>

<p>Sotuletinib (BLZ945) dihydrochloride is an orally administered, blood-brain barrier-permeable inhibitor specifically targeting CSF1-R with an IC50 of 1 nM.</p>

<p>c-Fms-IN-9 inhibits c-FMS/uFMS and uKIT with IC50 &lt;0.01μM and 0.1-1μM, from patent WO2014145023A1.</p>

<p>Leustroducsin A is an inducer of colony-stimulating factors (CSFs) extracted from Streptomyces platensis SANK 60191.</p>

<p>c-Fms-IN-7 is a cFMS inhibitor (IC50: 18.5 nM).</p>

<p>c-Fms-IN-8 is a colony-stimulating factor-1 receptor (CSF-1R, c-FMS) Type II inhibitor (IC50: 9.1 nM). It is compound 4a in the reference.</p>

<p>JNJ-28312141: oral CSF1R/FLT3 inhibitor, potential for treating acute myeloid leukemia, tumors, and bone events.</p>

<p>CSF1R-IN-4, a potent CSF-1R inhibitor, may impact TAM/glioma cell communication, with cancer research potential. (WO2021197276A1, compound 104)</p>

<p>c-Fms-IN-10 is a thieno[3,2-d]pyrimidine derivative, an FMS kinase inhibitor with IC50 of 2 nM, exhibiting anti-tumor properties.</p>

<p>CSF1R-IN-13: potent cancer research CSF1R inhibitor impacting cell growth regulation.</p>

<p>CSF1R-IN-8 (Compound 22) is a CSF-1R inhibitor (IC50: 0.012 μM).</p>

<p>CSF1R-IN-10 (Compound 48) is a CSF-1R inhibitor (IC50: 0.005 μM).</p>

<p>Leustroducsin C is an inducer of colony-stimulating factors CSF extracted from Streptomyces platensis SANK 60191.</p>

<p>CSF1R-IN-14, an isoindolinone derivative, powerfully inhibits CSF1R, with potential in cancer research. See WO2019134662A1, compound 1.</p>

<p>CSF1R-IN-12 is an effective CSF1R inhibitor. CSF1R-IN-12 has research potential in cancer diseases.</p>

<p>CSF1R-IN-7 is a highly selective CSF-1R inhibitor with good brain penetration for treatment of diseases associated with microglia-mediated neuroinflammation.</p>

<p>CSF1R-IN-9 (Compound 46) is a CSF-1R inhibitor (IC50: 0.028 μM).</p>

<p>CSF1R-IN-6, a compound, effectively inhibits macrophage CSF1R essential for survival and differentiation.</p>

<p>c-Fms-IN-2 is an inhibitor of c-FMS kinase (IC50 = 24 nM).</p>

<p>ABD-295, a biphenylsulfide derivative, inhibits osteoclasts and prevents bone loss in vitro and in vivo.</p>

<p>c-Fms-IN-6 is a potent inhibitor of c-FMS (IC50 ≤10 nM for unphosphorylated c-FMS) and also weakly inhibits unphosphorylated c-KIT and PDGFR (IC50: &gt; 1 μM).</p>

<p>IACS-9439 is a potent, selective, and orally active inhibitor of CSF1R, exhibiting a K(i) of 1 nM.</p>

<p>c-Fms-IN-1 is an inhibitor of c-FMS kinase (IC50 = 0.8 nM).</p>

<p>Chiauranib, a potent anticancer agent, inhibits angiogenesis kinases (VEGFR1-3, PDGFRα, c-Kit), Aurora B, and CSF1R with IC50 values of 1-9 nM.</p>

<p>c-Fms-IN-3 is a novel inhibitor of the c-FMS and can be used in studies about antirheumatic and anti-inflammatory diseases.</p>

<p>c-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor (IC50= 17 nM). c-Fms-IN-13 is an anti-inflammatory agent.</p>

<p>Pimicotinib (ABSK021) is a potent CSF1R inhibitor with antitumor activity and can be used to study advanced solid tumors.</p>

<p>CSF1R-IN-3 is an orally effective CSF-1R inhibitor with an IC50 value of 2.1 nM.</p>

<p>c-Fms-IN-14 (Example 76) is a potent inhibitor of the c-Fms kinase with an IC50 of 4 nM, utilized in cancer and autoimmune disease research [1].</p>

<p>Axl/Mer/CSF1R-IN-2 (Comp 4) serves as an inhibitor for Axl, Mer, and CSF1R [1].</p>

<p>Axl/Mer-IN-1 is a compound that functions as an inhibitor for Axl/Mer receptor tyrosine kinase (Axl/Mer RTK) and CSF1R, exhibiting dissociation constants (Kds)</p>

<p>Ataquimast is used in curing advanced receptor-positive breast cancer.</p>

<p>JTE-952: oral, selective Type II CSF-1R inhibitor, IC50 = 13 nM for CSF1R, 261 nM for TrkA, effective in mouse arthritis model.</p>

<p>CSF1R-IN-5: Potent CSF1R inhibitor, may alter TAM/glioma inflammatory exchanges, potential cancer research tool. (WO2021197276A1, Compound 11)</p>

<p>ARRY-382 is a highly selective oral inhibitor of CSF-1R with an IC50 of 9 nM.</p>

<p>Pimicotinib hydrochloride is an inhibitor of CSF1R, displaying antitumor activity.</p>

<p>Enrupatinib is an inhibitor of the colony stimulating factor 1 receptor (CSF1R), exhibiting antitumor activity.</p>

<p>c-Fms-IN-15 (compound 8g) is a potent inhibitor of FMS kinase, with an IC50 of 563 nM.</p>

<p>SJ-C1044 is an orally effective pan-RAF inhibitor demonstrating immunomodulatory and antitumor activities. It targets wild-type BRAF, wild-type CRAF, and BRAF(V600E) with IC50 values of 331, 257, and 187 nM, respectively. SJ-C1044 suppresses tumor cell proliferation by inhibiting kras activation and MEK-ERK phosphorylation. Additionally, it shows inhibition of VEGFR2, TIE2, and CSF1R, with IC50 values of 100, 23, and 235 nM respectively. The compound enhances the tumor immune microenvironment through inhibition of angiogenesis and modulation of macrophage function. SJ-C1044 is applicable for research in colorectal cancer.</p>

<p>GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor.</p>

<p>Leustroducsin B is a novel colony-stimulating factor (CSF) inducer extracted from Streptomyces platensis SANK 60191.</p>

<p>JNJ-6204 is a deuterated compound that efficiently inhibits CSNK1D and CSNK1E.</p>